IO Biotech (IOBT) Revenue & Revenue Breakdown
IO Biotech Revenue Highlights
IO Biotech Revenue by Period
IO Biotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
IO Biotech generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
IO Biotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.11M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
IO Biotech generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
IO Biotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IVA | Inventiva | $17.50M | $15.58M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| ASLN | ASLAN Pharmaceuticals | $12.00M | - |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| MNOV | MediciNova | $1.00M | - |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| ERAS | Erasca | - | - |
| ELYM | Eliem Therapeutics | - | - |
| IOBT | IO Biotech | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| PRDS | Pardes Biosciences | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| CMPX | Compass Therapeutics | - | - |
| PEPG | PepGen | - | - |
| CSBR | Champions Oncology | - | $12.02M |
IOBT Revenue FAQ
What is IO Biotech’s yearly revenue?
IO Biotech's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. IOBT's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is IO Biotech’s quarterly revenue?
IO Biotech's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). IOBT's quarterly revenue for Q4 2023 was $1.11M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is IO Biotech’s revenue growth rate?
IO Biotech's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.